Abstract
Regulation of the normal breast and prostate epithelial cells by steroid hormones has provided important insight into the control of malignant cells derived from these tissues. Over many years, strategies to disrupt ligand levels and block hormone binding to the estrogen receptor and androgen receptor have led to improved outcomes for breast and prostate cancer. Based on our understanding of hormone receptor function, numerous drugs have been approved for risk reduction, adjuvant therapy, and treatment of metastatic disease. In addition, new strategies are moving forward to further target receptor function by disrupting other signaling inputs. This review will address the current therapies and identify strategies for the future.
Original language | English (US) |
---|---|
Title of host publication | Endocrinology (Switzerland) |
Publisher | Springer Science and Business Media Deutschland GmbH |
Pages | 765-785 |
Number of pages | 21 |
DOIs | |
State | Published - 2018 |
Publication series
Name | Endocrinology (Switzerland) |
---|---|
ISSN (Print) | 2510-1927 |
ISSN (Electronic) | 2510-1935 |
Bibliographical note
Publisher Copyright:© Springer International Publishing AG 2018.
Keywords
- Androgen receptor
- Aromatase
- Breast cancer
- Estrogen receptor
- Lyase
- Prostate cancer